COMBiNATi believes that cancer will someday become a manageable chronic condition, instead of a deadly disease. With high throughput sequencing tools, it has become easier than ever to detect cancer early on. Using innovative strategies, growing numbers of targeted therapeutics have already been put into the development pipeline. However, for any chronic disease, successful monitoring of treatment efficacy and recurrence hinges on the timely and accurate quantification of disease-relevant biomarkers. COMBiNATi can become the leader in cancer recurrence monitoring by enabling patients and clinicians to have |confidence| when it comes to keeping an eye on cancer.
ResilienceIf it was easy, it would be done already
EmpoweringBring out the |best| in each other
AgilityRapid adaptation based on facts and data
Thoughtfulness Awareness of customer needs
EmpathyPatient centered solutions